United States: Long-Expected Omnibus Hipaa Rule Implements Significant Privacy And Security Regulations For Entities And Business Associates

Keywords: Health and Human Services, Privacy, Security, HIPAA,

On January 17, 2013, the Department of Health and Human Services (HHS) issued the final "omnibus" rule modifying the HIPAA Privacy, Security, Breach Notification and Enforcement Rules (Final Rule).1 As expected, the Final Rule extends the reach and limits of HIPAA's privacy and security provisions. The Final Rule implements mandated changes to HIPAA set forth by the Health Information Technology for Economic and Clinical Health Act (the HITECH Act), enacted February 17, 2009, and, to a lesser extent, the Genetic Information Nondiscrimination Act of 2008 (GINA).

The Final Rule becomes effective on March 26, 2013, with covered entities and business associates expected to comply with the new standards and implementation specifications by September 23, 2013 (180 days from the effective date).

As described in more detail below, the Final Rule expands certain HIPAA obligations to business associates and their subcontractors, modifies the breach notification standard, clarifies the civil monetary penalty structure and implements a variety of other provisions.

Business Associates

One of the most significant sections of the Final Rule relates to business associates of covered entities. The Final Rule broadens the definition of "business associate" to implement changes made under the HITECH Act, to conform to the provisions of the Patient Safety and Quality Improvement Act of 2005 (PSQIA), and to provide greater clarity to persons with access to protected health information generally.

A business associate now includes "a[ny] person who 'creates, receives, maintains or transmits' protected health information on behalf of a covered entity." (emphasis added). Specifically, the Final Rule identifies the following as business associates: patient safety organizations, health information entities, e-prescribing gateways and other contractors and subcontractors that provide data transmission services or facilitate access to protected health information (PHI). Subcontractors also now fall within the definition of business associate for whom covered entities ultimately will be responsible under the HIPAA Privacy Rule and Security Rule (the HIPAA Rules).

The Final Rule provides the following guidance concerning business associate agreements:

  • Vendors that contract with a covered entity to offer personal health records to patients on behalf of the covered entity are business associates and must enter into a written business associate agreement or similar arrangement with the covered entity.
  • Vendors that provide data transmission services to a covered entity that require access to PHI on a routine basis, regardless of whether such PHI is actually accessed by the vendors, are business associates and must enter into a written business associate agreement or similar arrangement with the covered entity.
  • Vendors with transient access to PHI and that act as mere conduits with regard to the transmission of PHI (e.g., the US Postal Service or Internet service providers) are not business associates and, as a result, a business associate agreement is not required.
  • Vendors that provide storage services with respect to PHI and have access to such PHI are business associates with which the covered entity should enter into a contractual relationship regarding such PHI.
  • A covered entity is not required to have a contractual relationship with its business associates' subcontractors. Instead, covered entities should obtain "satisfactory assurances required by the [HIPAA] Rules from their business associates." Business associates are required to enter into business associate agreements with those subcontractors that will be creating or receiving PHI on behalf of the business associates. Agreements must be written with a subcontractor's subcontractors "no matter how far 'down the chain' the information flows."

As a practical matter, the expansion of the definition of business associates likely will have limited impact on existing contractual relationships between covered entities and business associates. To the extent existing agreements lack such provisions, they can be amended to meet the expanded definition.

In addition, per the HITECH Act, the Final Rule also expands the applicability of the HIPAA Rules to business associates. For example, the Security Rule's administrative, physical, and technical safeguard requirements and documentation requirements now apply directly to business associates. HHS states that the extension of direct liability for compliance with the Security Rule is largely ministerial, as the Security Rule currently requires that covered entities establish business associate agreements that require the implementation of such safeguards. As a result, business associates and subcontractors should already have such security practices in place.

Similarly, the Final Rule makes business associates directly liable under the Privacy Rule for "uses and disclosures of [PHI] that are not in accord with its business associate agreement or the Privacy Rule." Moreover, business associates will also be directly liable under the Privacy Rule for failure to enter into business associate agreements with any subcontractors.

Breach Notification

In 2009, HHS issued an interim final rule to implement the breach notification provisions of the HITECH Act. Under the interim final rule, if a covered entity or business associate believed that an "unauthorized acquisition, access, use or disclosure of protected health information" had occurred, then, in order to determine whether such use or disclosure was a breach, the covered entity or business associate had to perform a comprehensive risk assessment to determine the likelihood that an individual would suffer harm as a result of such use or disclosure.

Unlike the interim final rule - in which the risk assessment was based on harm to an individual - the Final Rule presumes that any unauthorized access of PHI is a breach and requires that the risk assessment focus on the likelihood that the PHI has been compromised. If a covered entity or business associate that has suffered a breach can demonstrate that there is a "low probability" that the PHI has been compromised, notification may not be required. This "low probability" determination will be based on a risk assessment that includes the following four factors:

  • The nature and extent of PHI involved, including the types of identifiers and likelihood of re-identification;
  • The unauthorized person who used the PHI or to whom the disclosure of PHI was made;
  • Whether the PHI was actually viewed or acquired or, alternatively, if only the opportunity existed for the information to be viewed or acquired; or
  • The extent to which the risk to the PHI has been mitigated.

With regard to a business associate's notification obligations to a covered entity, the Final Rule establishes that a business associate must provide notice of breach of unsecured PHI to a covered entity "without unreasonable delay and in no case later than 60 days following the discovery of a breach."

With respect to notification to affected individuals of a breach, where a business associate is acting as an agent of the covered entity, discovery of a potential breach by the business associate is imputed to the covered entity. As a result, the covered entity will be required to provide notifications based on when the business associate discovers the breach and not when the business associate notifies the covered entity. HHS recommends that covered entities who have an agency relationship with their business associates address such issues in their business associate agreements.

Civil Monetary Penalties

The Final Rule's section on civil monetary penalties, while expected based on past rulemaking, is nevertheless noteworthy. On October 30, 2009, HHS issued an interim final rule that would revise HIPAA's enforcement provisions to incorporate the range of potential civil money penalty amounts set forth in section 13410(d) of the HITECH Act .

Prior to the HITECH Act, HIPAA's enforcement provisions authorized a civil penalty of not more than $100 for each violation, with the total amount imposed on a covered entity for all violations of an identical nature during a calendar year not to exceed $25,000. The HITECH Act instead imposed a tiered system featuring increasing penalty amounts for violations based on increasing levels of culpability associated with each tier. The Final Rule adopts the HITECH Act's tiered system. This tiered structure and corresponding penalties will apply to violations by covered entities and business associates.

Under the Final Rule, the tiered penalty scheme will be applicable to violations occurring on or after February 18, 2009. The penalty scheme is as follows, as summarized by the table published by HHS and copied here:

  • For violations in which the covered entity did not know and, by exercising reasonable diligence, would not have known that the covered entity violated a provision, an amount not less than $100 or more than $50,000 for each violation;
  • For a violation that was due to a reasonable cause, and not to willful neglect, an amount not less than $1000 or more than $50,000 for each violation;
  • For a violation that was due to willful neglect and was timely corrected, an amount not less than $10,000 or more than $50,000 for each violation; and
  • For a violation that was due to willful neglect and was not timely corrected, an amount not less than $50,000 for each violation.

The Final Rule sets a cap in that any penalty for violations of the same requirement or prohibition under any of the above categories may not exceed $1.5 million in a calendar year.

Categories of Violations and Respective Penalty Amounts Available

The maximum penalty will not be imposed for every violation. Instead, HHS has identified five categories that it will consider on a case-by-case basis in determining the amount of any civil money penalty. The Final Rule expanded these categories to include the following parameters. These will be fact-specific inquiries.

  • The nature and extent of any violation, including the number of individuals affected and the duration of the violation;
  • The nature and extent of any individual's resulting physical, financial, or reputational harm, including any hindrance to the individual's ability to obtain health care;
  • The history of prior noncompliance, including similar prior indications of noncompliance and the offending party's responses to them, and also history of compliance;
  • The financial condition of the offending party, including difficulties that could have affected compliance or that could cause a money penalty to jeopardize the future provision of health care; and
  • Such other matters as justice may require.

The Final Rule also limits the affirmative defenses available to an entity that violates HIPAA. A complete defense is available only if the violation was not due to willful neglect and was corrected within 30 days of when the entity knew, or by exercising "reasonable diligence" would have known, of the violation. This means that an entity's reasonable lack of knowledge of a violation alone will no longer constitute a complete defense, unless, in certain circumstances, it is timely corrected. Moreover, an employee or business associate's knowledge of a violation may be imputed to a covered entity. Finally, the HHS Secretary can waive the penalty to the extent that payment of the penalty would be excessive relative to the violation, and it is also within the Secretary's discretion to settle any issue or case.

Other Notable Components

The following section describes other notable provisions of the Final Rule.

Unsecured PHI. The Final Rule defines "unsecured PHI" to mean "protected health information that is not rendered unusable, unreadable, or indecipherable to unauthorized individuals through the use of a technology or methodology specified by the Secretary in guidance." Covered entities that implement the specified technologies and methodologies with respect to PHI are not required to provide notifications in the event of a breach of such information - that is, the information is not considered "unsecured" in such cases. The Secretary's guidance referenced in the Final Rule is guidance that was issued on April 19, 2009, which lists and describes "encryption" and "destruction" as the two technologies accepted.2

Fundraising The Final Rule expands the types of PHI that may be used (without the need for an authorization) for fundraising purposes. The additional types of PHI include date of birth, general department of service (e.g., cardiology), treating physician information, and outcome information. In addition, covered entities must provide a clear and conspicuous method for opting out of fundraising communications and the method must not result in undue burden or more than nominal cost to the individual.

Marketing. The Final Rule expands the uses of PHI that are considered to be marketing and, therefore, require an authorization. The Final Rule requires authorization for all treatment and health care operation communications that encourage the use of a product or service when a covered entity receives "financial remuneration" for making the communication from the third party whose product or service is being marketed.

Sale of PHI. The Final Rule defines sale of PHI as "a disclosure of [PHI] by a covered entity or business associate, if applicable, where the covered entity or business associate directly or indirectly receives remuneration from or on behalf of the recipient of the [PHI] in exchange for the [PHI]." Under the Final Rule, a covered entity must obtain an authorization for any disclosure of PHI that constitutes a sale of PHI.

Research. The Final Rule finalizes the HHS proposal to allow a blending of "conditioned" and "unconditioned" authorizations in a single document. Accordingly, HIPAA does not allow a covered entity to condition treatment on an individual executing an authorization. One of the exceptions is for clinical research, where the covered entity may condition the researchrelated treatment on execution of an authorization to use and disclose the individual's PHI in the research.

State Preemption. Although the Final Rule adopts preemption language to the extent that it can under previous proposals and rules under HIPAA and the HITECH Act, it can only preempt state law to the extent those laws are contrary to and more stringent than the Final Rule, as "Congress made it clear" that was its intention. Without further action from Congress, uniformity as to the various privacy laws will not be possible through rulemaking.

GINA. The Final Rule, in accordance with GINA, clarifies that genetic information is a type of health information and generally prohibits health plans from using or disclosing genetic information for underwriting purposes. "Genetic information" is broadly defined to include manifestation of a disease or disorder in a family member of an individual in addition to genetic tests of individuals and family members and requests for and receipt of genetic services. Other than clarifying that genetic information is health information, the provision does not impact health care providers.

Notices of Privacy Practices. Providers will need to update their Notice of Privacy Practices. They should advise individuals of the Final Rule's required changes, such as the duty of a covered entity to notify affected individuals of a breach of unsecured PHI and ensure that the Notice accurately describes privacy practices changes.

Forms. The Final Rule states that further educational materials and guidance can be found on its website at http://www.hhs.gov/ocr/ privacy/hipaa/understanding/index.html . Further, HHS has posted on its website sample business associate agreement provisions to help covered entities and business associates comply with the new business associate agreement requirements under the Final Rule.3

Footnotes

1 Available at http://www.ofr.gov/ OFRUpload/OFRData/2013-01073_PI.pdf .

2 See 75 Fed. Reg. 19006.

3 Available at http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/contractprov.html .

Previously published on February 11, 2013.

Visit us at mayerbrown.com

Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2013. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McLane Middleton, Professional Association
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McLane Middleton, Professional Association
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions